Coronavirus (COVID-19)
Learn more
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu- PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy.
Key Inclusion Criteria:
Primary Study Contact: Sierra Irizarry 860-972-4062
Research procedures may be conducted at the following locations: Hartford Hospital
Non-interventional study visits may take place at the following locations: HHC Medical Group at Manchester, Hospital of Central Connecticut, Midstate Medical Center
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209